aap Reports EUR 6.5 Million in Sales (+13%) and an increased EBITDA of EUR 0.8 Million (Q1 2010: EUR 0.2 Million)
(Thomson Reuters ONE) -
aap Implantate AG /
aap Reports EUR 6.5 Million in Sales (+13%) and an increased EBITDA of EUR 0.8
Million (Q1 2010: EUR 0.2 Million)
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG, a medical technology company listed in the Prime Standard
segment of the Frankfurt Stock Exchange, achieved sales totaling EUR 6.5 million
(previous year: EUR 5.8 million) in the first three months of the financial year
2011. Its EBITDA was EUR 0.8 million (previous year: EUR 0.2 million).
+-----------------------+------------+------------+--------+
| In EUR million | Q1/2011 | Q1/2010 | Change |
+-----------------------+------------+------------+--------+
| Sales | 6.5 | 5.8 | 13% |
+-----------------------+------------+------------+--------+
| EBITDA | 0.8 | 0.2 | >100% |
+-----------------------+------------+------------+--------+
| EBIT | 0.1 | -0.5 | n. a. |
+-----------------------+------------+------------+--------+
| Cash-EBIT | -0.5 | -1.1 | n. a. |
+-----------------------+------------+------------+--------+
| EBT | -0.1 | -0.7 | n. a. |
+-----------------------+------------+------------+--------+
| In EUR million | 31/3/2011 | 31/12/2010 | Change |
+-----------------------+------------+------------+--------+
| Equity (equity ratio) | 44.7 (71%) | 44.9 (70%) | -0.5% |
+-----------------------+------------+------------+--------+
| Balance sheet total | 63.4 | 63.6 | -0.2% |
+-----------------------+------------+------------+--------+
| Employees | 250 | 256 | -2% |
+-----------------------+------------+------------+--------+
In the first quarter of 2011 the Group's EBIT amounted to EUR 0.1 million
(previous year: EUR -0.5 million). Group EBT was EUR -0.1 million (previous
year: EUR -0.7 million). On a balance sheet total of EUR 63.4 million (Dec.
31, 2010: EUR 63.6 million) the equity ratio was 71 percent.
The main focal points of the corporate strategy in 2011 are the trauma and
cement & cementing techniques product groups including the integration of
infection care into these segments as well as the continued focus on customers,
costs and cash. aaps financial goal is to achieve a positive Cash-EBIT (EBIT
excluding internally produced and capitalized assets and respective
depreciation) by launching new and innovative products such as the WSG-product
line, license business deals, new OEM contracts and as well as through increased
direct sales. Thereby, aap wants to continue the positive trend of 2010 and
generate a profitable growth in 2011.
aap Implantate AG's first quarter 2011 results in full are available for
download at www.aap.de.
_________________________
aap Implantate AG (ISIN DE0005066609)
- Prime Standard/Regulated Market - All German stock markets -
aap is a medical technology company that develops, manufactures and markets
biomaterials and implants for the areas Ortho/Trauma/Spine. Its product
portfolio includes bone cements, bone graft substitutes, antibiotic carriers,
and implants for fracture healing and joint replacement. In addition to its
Berlin HQ the Company has sites in Dieburg near Frankfurt am Main and Nijmegen
in the Netherlands. aap Implantate AG stock has been listed in the Prime
Standard segment of the Frankfurt Stock Exchange since May 16, 2003.
For inquiries please contact:
aap Implantate AG, Nanette Huedepohl, Head of Corporate Communications,
Lorenzweg 5, 12099 Berlin, Germany, Tel.: +49 30 7501 9133, fax:
+49 30 7501 9290, n.huedepohl(at)aap.de
For more details please visit www.aap.de
--- End of Message ---
aap Implantate AG
Lorenzweg 5 Berlin Germany
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via Thomson Reuters ONE
[HUG#1514339]
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2011 - 07:53 Uhr
Sprache: Deutsch
News-ID 54497
Anzahl Zeichen: 5303
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 125 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap Reports EUR 6.5 Million in Sales (+13%) and an increased EBITDA of EUR 0.8 Million (Q1 2010: EUR 0.2 Million)"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
